Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tadalafil oral film - IntelGenx

Next Previous
Drug Profile

Tadalafil oral film - IntelGenx

Alternative Names: EXORDIA; INT-007; INT0007; INT0007/2006; Tadalafil - IntelGenx; Tadalafil film - IntelGenx

Latest Information Update: 28 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IntelGenx Corp.
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Gastrokinetics; Heart failure therapies; Indoles; Ischaemic heart disorder therapies; Pyridones; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Erectile dysfunction

Most Recent Events

  • 28 Apr 2023 Preregistration for Erectile dysfunction (In volunteers) in USA (PO) (IntelGenx website, April 2023)
  • 10 Nov 2020 IntelGenx has patent protection for tadalafil in USA
  • 28 Oct 2020 No recent reports of development identified for phase-I development in Erectile-dysfunction(In volunteers) in USA (PO, Film)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top